In this first stage of a pilot study that awaits confirmation with larger numbers of patients, our results suggest that vaccination targeting AR given prior to androgen deprivation therapy might improve outcome for patients with high-risk prostate cancer. Contrary to our initial hypothesis, this was not improved with the addition of PD-1 blockade, possibly due to the activation of regulatory CD4+T cells.

3 days ago

Journal

AR (Androgen receptor) • CD4 (CD4 Molecule)

Opdivo (nivolumab) • Firmagon (degarelix) • MVI-118

A Clinical Study of KLH-2109 in Patients With Endometriosis (clinicaltrials.gov)

P3, N=288, Active, not recruiting, Kissei Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting

5 days ago

Enrollment closed

leuprolide acetate for depot suspension • Yselty (linzagolix)

RELAX: Relugolix for Endometriosis Associated Pain (clinicaltrials.gov)

P=N/A, N=33, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

7 days ago

New trial • Real-world evidence

Orgovyx (relugolix)

22d

REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov)

P2, N=94, Active, not recruiting, Emory University | Trial completion date: Dec 2025 --> Oct 2026

22 days ago

Trial completion date

Orgovyx (relugolix) • leuprolide acetate for depot suspension

to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia (clinicaltrials.gov)

P3, N=254, Recruiting, JW Pharmaceutical

1 month ago

New P3 trial

Yselty (linzagolix)

2ms

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (clinicaltrials.gov)

P3, N=333, Not yet recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

2 months ago

New P3 trial

Cetrotide (cetrorelix)

2ms

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (clinicaltrials.gov)

P2, N=30, Recruiting, Memorial Sloan Kettering Cancer Center

2 months ago

New P2 trial

Firmagon (degarelix)

2ms

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial (clinicaltrials.gov)

P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Dec 2026

2 months ago

Trial completion date • Trial primary completion date

Orgovyx (relugolix)

2ms

Insights in Endocervical Mucus Secretion (clinicaltrials.gov)

P4, N=15, Recruiting, Oregon Health and Science University | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Jan 2026

2 months ago

Enrollment open • Trial initiation date

Orgovyx (relugolix)

2ms

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)

P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

2 months ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

Chr t(15;17)

cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)